{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:23:18Z","timestamp":1789539798262,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.lungcan.2025.108478","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:42:37Z","timestamp":1741783357000},"page":"108478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced\/recurrent non-small cell lung cancer: Post-marketing surveillance"],"prefix":"10.1016","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2960-4364","authenticated-orcid":false,"given":"Takashi","family":"Seto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2733-3265","authenticated-orcid":false,"given":"Sayuri","family":"Nakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4769-412X","authenticated-orcid":false,"given":"Hiroshi","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6419-1120","authenticated-orcid":false,"given":"Ayako","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":false,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108478_b0005","author":"Ferlay","year":"2024","journal-title":"Global Cancer Observatory: Cancer Today \u2013 Lung Cancer Factsheet"},{"key":"10.1016\/j.lungcan.2025.108478_b0010","author":"Ferlay","year":"2024","journal-title":"Global Cancer Observatory: Cancer Today \u2013 Japan Factsheet"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108478_b0015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12890-023-02610-5","article-title":"Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study","volume":"23","author":"Kobayashi","year":"2023","journal-title":"BMC Pulm. Med."},{"issue":"17","key":"10.1016\/j.lungcan.2025.108478_b0020","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/1759-7714.14900","article-title":"Survival and medical costs of non-small cell lung cancer patients according to the first-line treatment: an observational study using the Kyoto City Integrated Database","volume":"14","author":"Shimamoto","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.lungcan.2025.108478_b0025","unstructured":"Japan Lung Cancer Society, Lung cancer treatment guidelines \u2013 including malignant pleural mesothelioma and thymic tumors: 2023 edition [in Japanese], 2023. https:\/\/www.haigan.gr.jp\/guideline\/2023\/. (Accessed 28 February 2024)."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108478_b0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/curroncol29020057","article-title":"ROS-1 fusions in non-small-cell lung cancer: evidence to date","volume":"29","author":"Gendarme","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2025.108478_b0035","unstructured":"Japan Lung Cancer Society, Stage IV non-small cell lung cancer: 2023 edition [in Japanese], 2023. https:\/\/www.haigan.gr.jp\/guideline\/2023\/1\/2\/230102070100.html#j_7-1-3_1. (Accessed 26 June 2024)."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108478_b0040","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108478_b0045","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2025.108478_b0050","unstructured":"Chugai Pharmaceutical Co., Ltd., Chugai obtains approval for additional indication of Rozlytrek for ROS1 fusion-positive non-small cell lung cancer, 2020. https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20200221160001_702.html. (Accessed 28 February 2024)."},{"key":"10.1016\/j.lungcan.2025.108478_b0055","unstructured":"Chugai Pharmaceutical Co., Ltd., Rozlytrek\u00ae (entrectinib) capsules: package insert [in Japanese], 2023. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/450045_4291061M1025_1_09. (Accessed 7 March 2024)."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108478_b0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"i. trial, Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108478_b0065","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108478_b0070","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2025.108478_b0075","unstructured":"Ministry of Health Labor and Welfare of Japan, Ministerial ordinance on good post-marketing study practice for drugs, 2004. https:\/\/www.mhlw.go.jp\/web\/t_doc?dataId=81aa6623&dataType=0&pageNo=1. (Accessed 15 May 2024)."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108478_b0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2025.108478_b0085","unstructured":"Japan Clinical Oncology Group, Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [in Japanese], 2017. https:\/\/jcog.jp\/doctor\/tool\/ctcaev4\/. (Accessed 29 February 2024)."},{"key":"10.1016\/j.lungcan.2025.108478_b0090","unstructured":"Pharmaceuticals and Medical Devices Agency, Rozlytrek capsules 100mg\/200 mg (entrectinib) (ROS1 gene fusion-positive non-small cell lung cancer). The common technical document module 2: quality overall summary, module 2.5 clinical overview [in Japanese], 2020. https:\/\/www.pmda.go.jp\/drugs\/2020\/P20200225007\/index.html. (Accessed 10 April 2024)."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108478_b0095","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3390\/cancers15061766","article-title":"Hepatotoxicity of small molecule protein kinase inhibitors for cancer","volume":"15","author":"Vigan\u00f2","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108478_b0100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0169-5002(00)00227-0","article-title":"Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation","volume":"32","author":"Rodrigus","year":"2001","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108478_b0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108478_b0110","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108478_b0115","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41467-019-11496-z","article-title":"The new-generation selective ROS1\/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models","volume":"10","author":"Katayama","year":"2019","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.lungcan.2025.108478_b0120","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2217\/cer-2021-0131","article-title":"Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC","volume":"10","author":"Doebele","year":"2021","journal-title":"J. Comp. Eff. Res."},{"issue":"17","key":"10.1016\/j.lungcan.2025.108478_b0125","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2217\/fon-2021-1102","article-title":"Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data","volume":"18","author":"Tremblay","year":"2022","journal-title":"Future Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225003708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225003708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:25:35Z","timestamp":1777782335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225003708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":25,"alternative-id":["S0169500225003708"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108478","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced\/recurrent non-small cell lung cancer: Post-marketing surveillance","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108478"}}